Search results for "Abstracts"

PNR-35CNS HGNET-BCOR - MOLECULAR CHARACTERIZATION AND IDENTIFICATION OF POSSIBLE THERAPEUTIC TARGETS OF A NEW BRAIN TUMOR ENTITY

2016

26th Annual Computational Neuroscience Meeting (CNS*2017): Part 2

2017

International audience; No abstract available

CENTENARIANS TRANSCRIPTOME IS UNIQUE AND REVEALS A ROLE OF BCL-XL IN SUCCESSFUL AGING

2017

Centenarians not only enjoy an extraordinary aging, but also show a compression of morbidity. We identified 1721 mRNAs differentially expressed by PMBCs from centenarians when compared with septuagenarians and young people. Sub-network analysis led us to identify Bcl-xL as an important gene up-regulated in centenarians. We found that centenarians display lower plasma cytochrome C levels, higher mitochondrial membrane potential and also less cellular damage accumulation. Immune function is significantly impaired in septuagenarians compared with young people whereas centenarians maintain it. To further ascertain the functional role of Bcl-xL in cellular aging, we found in transduced lymphocyt…

AB052. P-20. Phase 2, open-label study of second-line M7824 treatment in patients with locally advanced or metastatic biliary tract cancer

2019

BACKGROUND: Transforming growth factor β (TGF-β) signaling promotes tumor immunosuppression; its inhibition in the tumor microenvironment may enhance the response to anti-PD-L1 treatment. M7824 is an innovative first-in-class bifunctional fusion protein composed of 2 extracellular domains of TGF-βRII (a TGF-β “trap”) fused to a human IgG1 mAb against PD-L1. Building upon encouraging efficacy observed in a phase 1 study, the present study will evaluate M7824 clinical benefit in patients with pretreated biliary tract cancer (BTC). METHODS: This multicenter, international trial is evaluating M7824 monotherapy in patients with locally advanced or metastatic (LA/M) BTC unselected for tumor PD-L1…

149. Immunogenicity, Safety, and Post-hoc Efficacy Assessment of the Adjuvanted Recombinant Zoster Vaccine in Adults with Hematologic Malignancies: A…

2018

Abstract Background Patients with hematologic malignancies treated with anticancer immunosuppressive therapies (ITs) are at increased risk of herpes zoster (HZ). In a previous report of this phase 3, observer-blind, multicenter trial (NCT01767467), the adjuvanted recombinant zoster vaccine (RZV) was shown to be immunogenic and well-tolerated in ≥18 years of age patients with hematologic malignancies who completed or were undergoing anticancer IT.1 Here we report end-of-study results from the same trial. Methods Participants were randomized 1:1 to receive 2 doses of RZV or placebo (PL) 1–2 months apart, either ≥10 days before or after a cancer therapy cycle, or 10 days to 6 months after canc…

A call for dissensus in art education!

2019

This article argues for the relevance of the term dissensus by the French philosopher Jacques Rancière in an art educational context in particular and an educational context in general. This argument is based on research referred to in this article, where the author made use of dissensus to analyse how encounters with contemporary art contribute to movements in youngsters’ ways of relating to artworks and the environment that surrounds them, as well as changes in the ways of relating to themselves and others ‐ what here is called events of subjectivation. As dissensus is seen as a premise for subjectivation, the author argues for initiating dissensus by introducing students to both art and …

What happens to the BRONJ patients when re-classified according to the novel SICMF-SIPMO recommendations? Our experience

2014

Background. Since 2009, according to the American Association of Oral and Maxillofacial Surgeons staging system (AAOMS-SS), Bisphosphonate Related Osteonecrosis of the Jaw (BRONJ) has been defined by the presence of bone exposition; in absence of this condition, patients presenting other unspecific clinical and/or radiological signs of disease were classified into the “stage 0”. In 2012, the Italian Society of Maxillo-Facial Surgery (SICMF) and the Italian Society of Oral Pathology and Medicine (SIPMO) redefined BRONJ, as an adverse drug event, with several clinical forms (exposed and not-exposed), and updated the staging system, abolishing the stage 0. Aim of this study was to re-classify …

LAB-STEM CELLS

2012

EMBEDDING CONTEXT IN INVESTIGATIONS OF AFFECTIVE VARIABILITY: AGE DIFFERENCES IN AFFECT-HEALTH LINKS

2017

Context plays a potentially important role in explaining variability in affective experiences and yet, has often been overlooked in this line of research. The current study used data from a lifespan sample of 398 German participants ranging between 12–88 years of age (M = 40, SD = 20). Participants completed computer assisted personal interviews regarding health and well-being measures, as well as experience sampling assessments of daily affective experiences and events (e.g., uplifts). Three indices of positive affect (PA) were created: mean PA, PA reactivity to uplifts, and PA variability. In general, greater mean PA and lower PA reactivity and variability were associated with better heal…

IN THE EYE OF THE BEHOLDER: NEGATIVE AFFECT VALUATION IN LATER ADULTHOOD

2018

Affective values may shape how affect is linked to health and well-being. Much of the work to date, however, has focused mostly on younger, European American adult samples. Yet, emotional experiences are known to take on greater importance in later life. In the current study, 313 participants (65+ years old) from the Daily Experiences and Well-Being Study (DEWS) completed baseline interviews, questionnaires, and 4–5 days of ecological momentary assessments (EMA). The baseline EMA surveys assessed momentary affect whereas the questionnaires assessed negative affect valuation (NAV): the extent to which people recognize value in negative emotional experiences in terms of their pleasantness, ap…